Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

Nitrosamine Risk Assessments

The understanding of the process chemistry with respect to the risk of API containing N-Nitrosamines as impurities is essential to ensure patient safety and meet regulatory requirements. Sai Life Sciences has a robust end to end process to assess risk and support customers in the development of control strategies.

Nitrosamine Risk Assessments
Mitigate N-Nitrosamine formation risks


  • Robust risk assessment process as part of the quotation, manufacture and lifecycle management stages.
  • Vendor assessment process covering raw materials and starting materials.
  • Ongoing risk assessment process to mitigate any risk of N-Nitrosamine contamination as a result of the utilisation of process equipment.
  • Expertise in process chemistry to understand and mitigate the risk of N-Nitrosamine formation.
  • Expertise in the utilisation of in-silico purge calculations and spiking/purge studies to support control strategy development.
  • State of the art analytical instrumentation and expertise capable of meeting regulatory requirements for the control of N-Nitrosamines.
  • Capability to carry out Mutagenicity testing (Non-GLP Studies such as; Ames, In Vitro Chromosome Aberration Assay, and In Vivo Micronucleus Test)


  • 100+ projects (RM, KSM, intermediates and API) were assessed and evaluated by Expert Panel Team at Sai and provided N-Nitrosamine Assessment reports for regulatory requirement as per client request
  • Synthetic route designs which minimise the risk of N-nitrosamine formation
  • Utilisation of purge calculations to inform the approach to regulatory control strategies.

State of the art analytical Instrumentation

  • Sciex LC-MS/MS ion trap
  • Shimadzu GC-MS/MS ion trap
  • Methodology has been established for a number of the N-Nitrosamines with ADIs approved by the regulatory authorities with a limit of quantification of 10ppb
  • Flexibility to extend the approach to other N-Nitrosamines of interest